Stimulant shortage status by drug and strength, DEA production quota changes, telehealth controlled substance prescribing rule changes and deadlines, insurer prior authorization and quantity limit changes, generic launches and price drops, adult ADHD diagnosis guideline changes, school accommodation rule changes, and online ADHD clinic enforcement actions, with the drug or rule first.